Search results for "2712 Endocrinology"

showing 10 items of 18 documents

Women reduced the sex difference in open-water ultra-distance swimming - La Traversee Internationale du Lac St-Jean, 1955-2012

2014

In La Traversée Internationale du Lac St-Jean, held between 1955 and 2012 in Canada, the fastest women (r2 = 0.61, p < 0.0001) and men (r2 = 0.66, p < 0.0001) improved swimming speed over the years but the sex difference remained unchanged at 8.8% ± 5.6% (r2 = 0.069, p = 0.065). Annually, for the 3 fastest swimmers, both women (r2 = 0.53, p < 0.0001) and men (r2 = 0.71, p < 0.0001) improved swimming speed between 1973 and 2012 and the sex difference decreased (r2 = 0.29, p = 0.0016) from 14.4% ± 11.0% (1973) to 3.7% ± 1.4% (2012).

11035 Institute of General PracticeNutrition and DieteticsPhysiologyEndocrinology Diabetes and Metabolism610 Medicine & healthMEN1314 PhysiologyGeneral MedicinePERFORMANCEFEMALE2712 Endocrinology Diabetes and MetabolismSwimming speed2737 Physiology (medical)Open waterGeographyWater SportPhysiology (medical)2916 Nutrition and Dietetics[ SCCO ] Cognitive scienceSPEEDENDURANCE SWIMMERSDemographyZURICH
researchProduct

Ethnic differences in serum lipoproteins and their determinants in South African women

2010

2712 Endocrinology Diabetes and Metabolismlow-density lipoprotein South African women10076 Center for Integrative Human Physiology10265 Clinic for Endocrinology and Diabetology570 Life sciences; biology610 Medicine & health1310 Endocrinology
researchProduct

Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndrome…

2008

Somatostatin-producing neuroendocrine tumors (SOM-NETs) of the duodenum and pancreas appear to be heterogeneous. To determine their clinicopathological profiles, respective data were analyzed on a series of 82 duodenal and 541 pancreatic NETs. In addition, the clinical records of 821 patients with duodenal or pancreatic NETs were reviewed for evidence of a somatostatinoma syndrome. Predominant or exclusive expression of somatostatin was found in 21 (26%) duodenal and 21 (4%) pancreatic NETs. They were classified as sporadic (n=31) or neurofibromatosis type 1 (NF1)-associated duodenal NETs (n=3), gangliocytic paragangliomas (GCPGs; n=6), or poorly differentiated neuroendocrine carcinomas (pd…

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism610 Medicine & healthNeuroendocrine tumorsGastroenterologyParagangliomaEndocrinologyDuodenal NeoplasmsInternal medicine10049 Institute of Pathology and Molecular PathologySomatostatinomaMultiple Endocrine Neoplasia Type 1MedicineHumansMEN11306 Cancer ResearchGenetic Predisposition to DiseaseNeurofibromatosisMultiple endocrine neoplasia610 Medicine & healthAgedAged 80 and overbusiness.industryIncidenceSyndromeSomatostatinomaMiddle Agedmedicine.diseasePrognosis1310 EndocrinologyPancreatic Neoplasms2712 Endocrinology Diabetes and MetabolismNeuroendocrine Tumorsmedicine.anatomical_structureSomatostatinOncologyDuodenum570 Life sciences; biology2730 OncologyFemalebusinessPancreasSomatostatinFollow-Up Studies
researchProduct

Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency

2008

Abstract Objective Several studies have suggested that lipoproteins generated during the post-prandial phase are highly atherogenic, with modifications in low-density lipoproteins (LDL) size and density. In the present study we assessed post-prandial variations in LDL size and subclasses in patients with growth hormone deficiency (GHD). Design We studied in 12 hypopituitary patients with GHD and 10 healthy control subjects matched for gender, age and body mass index (BMI) post-prandial variations after a standardized meal consisting of 35% fat, 45% carbohydrate and 20% of protein (Clinutren Mix ® , Nestle) and containing calories corresponding to 1/3 of estimated basal metabolic rate. Blood…

AdultMalemedicine.medical_specialtyCalorieEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPilot ProjectsHypopituitarismSubclassGrowth hormone deficiencyEndocrinologyInternal medicinemedicineHumansLipoproteinGel electrophoresisMealbusiness.industryMiddle AgedCarbohydratePost-prandialPostprandial Periodmedicine.diseaseSmall dense LDL1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologyCase-Control StudiesGrowth HormoneBasal metabolic rateGrowth hormone deficiencyFemalelipids (amino acids peptides and proteins)businessBody mass indexGrowth Hormone & IGF Research
researchProduct

Recommendations on the diagnosis and management of Niemann-Pick disease type C

2009

Niemann-Pick disease type C (NP-C) is a lysosomal storage disease in which impaired intracellular lipid trafficking leads to excess storage of cholesterol and glycosphingolipids in the brain and other tissues. it is characterized clinically by a variety of progressive, disabling neurological symptoms including clumsiness, limb and gait ataxia, dysarthria, dysphagia and cognitive deterioration (dementia). Until recently, there has been no disease-modifying therapy available for NP-C, with treatment limited to supportive measures. In most countries, NP-C is managed through specialist centers, with non-specialist support provided locally. However, effective patient Support is hampered by the a…

Adultmedicine.medical_specialtyNeurology1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistry03 medical and health sciencesDysarthriaYoung Adult0302 clinical medicineEndocrinology1311 GeneticsGeneticsLysosomal storage diseasemedicine1312 Molecular BiologyDementiaHumansMass ScreeningIntensive care medicineChildMolecular BiologyMass screening030304 developmental biology0303 health sciencesNiemann–Pick disease type Cbusiness.industryInfant NewbornInfantNiemann-Pick Disease Type CMiddle Agedmedicine.disease3. Good health1310 Endocrinology2712 Endocrinology Diabetes and Metabolism10036 Medical ClinicChild PreschoolPhysical therapyGait Ataxiamedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

2009

Summary Objective  Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 ± 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. Methods and results  Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elev…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthCerebroCoronary artery diseaseEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansFamily historyLow-density lipoproteins (LDL metabolic syndromeAgedMetabolic SyndromeUnivariate analysisbusiness.industryMiddle Agedmedicine.disease1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologymedicine.anatomical_structureSmall dense low-density lipoproteins cardio events cerebro-vascular events the metabolic syndromeCardiovascular DiseasesPredictive value of testsCirculatory systemFemaleMetabolic syndromebusinessBlood vesselFollow-Up Studies
researchProduct

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

2018

Abstract Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be ‘silent’ or ‘asymptomatic’, but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anti…

Blood Glucoselcsh:Diseases of the circulatory (Cardiovascular) systemEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and DiabetologyDiseaseType 2 diabetes030204 cardiovascular system & hematologySilent0302 clinical medicineRisk FactorsMass ScreeningAsymptomatic ; Atypical ; Cardiovascular disease ; Screening ; Silent ; Type 2 diabetes ; Unrecognised.Type 2 diabetesCardiovascular diseasePrognosisAsymptomatic3. Good health2712 Endocrinology Diabetes and MetabolismCardiovascular DiseasesScreeningmedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyPrognostic factor030209 endocrinology & metabolism610 Medicine & healthRisk AssessmentAsymptomatic2705 Cardiology and Cardiovascular Medicine03 medical and health sciencesPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIntensive care medicineUnrecognisedbusiness.industrymedicine.diseaseEarly DiagnosisDiabetes Mellitus Type 2lcsh:RC666-7012724 Internal MedicineHeart failureAsymptomatic DiseasesCommentarybusinessAtypicalBiomarkers
researchProduct

Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)

2022

AbstractDyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowe…

Diabetes Mellitus Type 2 / diagnosisDyslipidemias / drug therapyEndocrinology Diabetes and Metabolism610 Medicine & health2705 Cardiology and Cardiovascular MedicineCardiovascular risk Diabetes Individual therapy approach Lipid lowering therapy StatinsHumansIndividual therapy approachDyslipidemiasHypolipidemic AgentsDiabetes Mellitus Type 2 / epidemiologyDiabetesStatinsCholesterol LDLCardiovascular riskAtherosclerosisDyslipidemias / diagnosis2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 22724 Internal MedicineDyslipidemias / epidemiology10209 Clinic for CardiologyProprotein Convertase 9Diabetes Mellitus Type 2 / drug therapyCardiology and Cardiovascular MedicineLipid lowering therapy
researchProduct

Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes.

2008

AIMS: Women with gestational diabetes are more likely to develop Type 2 diabetes and cardiovascular disease after pregnancy; however, the exact nature of the lipid alterations present is not clear. In Mediterranean women with gestational diabetes, we measured low-density lipoprotein (LDL) size and all seven subclasses, as well as the 'atherogenic-lipoprotein phenotype'[ALP, e.g. concomitant presence of elevated triglycerides, reduced high-density lipoprotein (HDL)-cholesterol and increased small, dense LDL]. METHODS: In 27 women with gestational diabetes and 23 healthy pregnant women matched for age, weeks of gestation and body mass index, we measured plasma lipids and LDL size and subclass…

Electrophoresismedicine.medical_specialtyAtherogenic lipoprotein phenotypeEndocrinology Diabetes and MetabolismPregnancy Complications Cardiovascular10265 Clinic for Endocrinology and Diabetology610 Medicine & healthGestational AgeType 2 diabeteschemistry.chemical_compoundEndocrinologyPregnancyInternal medicineDiabetes mellitusInternal Medicinedense LDL diabetes HDL-cholesterol pregnancy small triglyceridesMedicineHumansTriglyceridesPregnancybusiness.industryCholesterolMediterranean RegionCholesterol HDLGestational agemedicine.disease1310 EndocrinologyGestational diabetesLipoproteins LDL2712 Endocrinology Diabetes and MetabolismDiabetes GestationalEndocrinologyCholesterolchemistryDiabetes Mellitus Type 22724 Internal MedicinePregnancy Trimester SecondFemalelipids (amino acids peptides and proteins)businessBody mass indexDiabetic AngiopathiesLipoprotein
researchProduct

Miglustat in patients with Niemann-Pick disease Type C (NP-C): A multicenter observational retrospective cohort study

2009

Miglustat has been shown to stabilize disease progression in children, juveniles and adults with Niemann-Pick disease type C (NP-C), a rare genetic disorder characterized by progressive neurological deterioration. We report findings from a retrospective observational cohort study assessing the effects of miglustat on neurological disease progression in patients treated in the clinical practice setting. Data from all NP-C patients prescribed miglustat at 25 expert centers were evaluated using a disease disability scale. The scale analyzed four key parameters of neurological disease progression in NP-C (ambulation, manipulation, language, swallowing). Mean individual parameter scores and a co…

MalePediatricsmedicine.medical_specialty1-Deoxynojirimycin1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistryCohort StudiesEndocrinology1311 GeneticsMiglustat1312 Molecular BiologyGeneticsHumansMedicineEnzyme InhibitorsChildMolecular BiologyRetrospective StudiesNiemann–Pick disease type Cbusiness.industryNiemann-Pick Disease Type CRetrospective cohort studymedicine.disease1310 EndocrinologyClinical trial2712 Endocrinology Diabetes and MetabolismTreatment Outcome10036 Medical ClinicCohortFemalebusinessNiemann–Pick diseaseCohort studymedicine.drugMolecular Genetics and Metabolism
researchProduct